论文部分内容阅读
目的:研究在治疗2型糖尿病过程中采取联合瑞格列奈注射甘精胰岛素的方法所带来的临床效果。方法:为了更好地体现甘精胰岛素联合瑞格列奈治疗2型糖尿病的临床效果,我们选择比较常见的对比法。选取我院2011年-2013年间的80例2型糖尿病患者,将其随机分成观察组与对照组两组,进行治疗过程中,给予对照组患者常规的治疗方式,即在治疗过程中使用预混胰岛素;对于观察组患者,我们在治疗过程中采用甘精胰岛素联合瑞格列奈的方法来进行。一段时间过后,分别观察两组患者的低血糖、餐后2小时的血糖、空腹时的血糖以及糖化血红蛋白的情况。结果:对两组患者进行观察发现,经过治疗,观察组患者的糖化血红蛋白降低的效率远远优于对照组,而空腹以及餐后2小时的血糖含量并没有较大差异。结论:在治疗2型糖尿病患者过程中,采用甘精胰岛素联合瑞格列奈的方式可以更好地降低患者的糖化血红蛋白,在安全性能以及临床疗效上也有很大优势,值得我们进行大力推广。
OBJECTIVE: To study the clinical effects of combining gliclazin with repaglinide in the treatment of type 2 diabetes mellitus. Methods: In order to better reflect the clinical effect of glargine and repaglinide on type 2 diabetes mellitus, we chose the more common method of contrast. 80 patients with type 2 diabetes in our hospital from 2011 to 2013 were randomly divided into two groups: observation group and control group. In the course of treatment, the patients in control group were given routine treatment, that is, the use of premix Insulin; for the observation group of patients, we use glargine combined with repaglinide in the treatment process. After a period of time, were observed in two groups of patients with hypoglycemia, 2-hour postprandial blood glucose, fasting blood glucose and glycosylated hemoglobin situation. Results: The two groups of patients were observed after treatment, the observation group patients with glycosylated hemoglobin reduction efficiency is much better than the control group, and fasting and postprandial blood glucose levels did not differ significantly. Conclusion: In the treatment of patients with type 2 diabetes, the use of glargine and repaglinide can better reduce the patient’s HbA1c, and has great advantages in safety and clinical efficacy, which deserves our promotion.